Which statement about ipratropium bromide in combination therapy is true?

Which statement about ipratropium bromide in combination therapy is true?

• A. It is administered with albuterol
• B. It should not be used with any other bronchodilators
• C. It has no side effects
• D. It is only used in anorexia

Answer: (A)

The main concept is that ipratropium bromide is used in combination with a beta-agonist because they provide complementary bronchodilation through different mechanisms. Ipratropium blocks muscarinic receptors in the airways, reducing parasympathetic-driven bronchoconstriction, while albuterol stimulates beta-2 receptors to relax smooth muscle. Together, they produce greater and faster bronchodilation than either alone, which is why this combination is a common approach in acute bronchospasm seen in asthma or COPD and is often given by inhalation or nebulizer in emergency care. It’s not true that it must not be used with other bronchodilators, and ipratropium can cause side effects such as dry mouth and taste changes, so it’s not correct to say it has no side effects or is limited to anorexia.

The main concept is that ipratropium bromide is used in combination with a beta-agonist because they provide complementary bronchodilation through different mechanisms. Ipratropium blocks muscarinic receptors in the airways, reducing parasympathetic-driven bronchoconstriction, while albuterol stimulates beta-2 receptors to relax smooth muscle. Together, they produce greater and faster bronchodilation than either alone, which is why this combination is a common approach in acute bronchospasm seen in asthma or COPD and is often given by inhalation or nebulizer in emergency care. It’s not true that it must not be used with other bronchodilators, and ipratropium can cause side effects such as dry mouth and taste changes, so it’s not correct to say it has no side effects or is limited to anorexia.